Research progress of idiopathic membranous nephropathy complicated with venous thromboembolism

doi:10.3877/cma.j.issn.2095-3216.2020.05.006

Abstract

Abstract:

Patients with idiopathic membranous nephropathy (IMN) are often complicated with venous thromboembolism (VTE), including pulmonary thromboembolism (PTE), and deep venous thrombosis (DVT), etc. VTE is not only an important cause for disease prolongation and death of patients with IMN, but also affects renal biopsy so much that some patients′ pathological types can′t be clarified, which has a great impact on the efficacy and prognosis of the disease. At present, there are still controversies regarding not only the mechanism by which patients with IMN are prone to be complicated with VTE, but also the preventive anticoagulation treatment for non-VTE patients. This article reviewed the research progress of pathogenesis, diagnosis, and treatment of IMN complicated by VTE.

Key words: Idiopathic membranous nephropathy, Venous thromboembolism

Chunlei Lu, Changhua Liu. Research progress of idiopathic membranous nephropathy complicated with venous thromboembolism[J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2020, 09(05): 220-223.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhsbyjdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3216.2020.05.006

https://zhsbyjdzzz.cma-cmc.com.cn/EN/Y2020/V09/I05/220

References 34

[1]	Hou JH, Zhu HX, Zhou ML, et al. Changes in the spectrum of kidney diseases: an analysis of 40，759 biopsy-proven cases from 2003 to 2014 in China [J]. Kidney Dis (Basel), 2018, 4(1): 10-19.
[2]	Couser WG. Primary membranous nephropathy [J]. Clin J Am Soc Nephrol, 2017, 12(6): 983-997.
[3]	Kerlin BA, Ayoob R, Smoyer WE. Epidemiology and pathophysiology of nephrotic syndrome-associated thromboembolic disease [J]. Clin J Am Soc Nephrol, 2012, 7(3): 513-520.
[4]	Bellomo R, Wood C, Wagner I, et al. Idiopathic membranous nephropathy in an Australian population: the incidence of thromboembolism and its impact on the natural history [J]. Nephron, 1993, 63(2): 240-241.
[5]	Lionaki S, Derebail VK, Hogan SL, et al. Venous thromboembolism in patients with membranous nephropathy [J]. Clin J Am Soc Nephrol, 2012, 7(1): 43-51.
[6]	Kumar S, Chapagain A, Nitsch D, et al. Proteinuria and hypoalbuminemia are risk factors for thromboembolic events in patients with idiopathic membranous nephropathy: an observational study [J]. BMC Nephrol, 2012, 13: 107.
[7]	Li SJ, Guo JZ, Zuo K, et al. Thromboembolic complications in membranous nephropathy patients with nephrotic syndrome-a prospective study [J]. Thromb Res, 2012, 130(3): 501-505.
[8]	Gregson J, Kaptoge S, Bolton T, et al. Cardiovascular risk factors associated with venous thromboembolism [J]. JAMA Cardiol, 2019, 4(2): 163-173.
[9]	Eneman B, Levtchenko E, van den Heuvel B, et al. Platelet abnormalities in nephrotic syndrome [J]. Pediatr Nephrol, 2016, 31(8): 1267-1279.
[10]	Eneman B, Elmonem MA, van den Heuvel LP, et al. Pituitary adenylate cyclase-activating polypeptide (PACAP) in zebrafish models of nephrotic syndrome [J]. PLoS One, 2017, 12(7): e0182100.
[11]	Eneman B, Freson K, van den Heuvel L, et al. Pituitary adenylate cyclase-activating polypeptide deficiency associated with increased platelet count and aggregability in nephrotic syndrome [J]. J Thromb Haemost, 2015, 13(5): 755-767.
[12]	Barbour SJ, Greenwald A, Djurdjev O, et al. Disease-specific risk of venous thromboembolic events is increased in idiopathic glomerulonephritis [J]. Kidney Int, 2012, 81(2): 190-195.
[13]	Hamano K, Iwano M, Akai Y, et al. Expression of glomerular plasminogen activator inhibitor type 1 in glomerulonephritis [J]. Am J Kidney Dis, 2002, 39(4): 695-705.
[14]	Gao C, Xie R, Yu C, et al. Procoagulant activity of erythrocytes and platelets through phosphatidylserine exposure and microparticles release in patients with nephrotic syndrome [J]. Thromb Haemost, 2012, 107(4): 681-689.
[15]	Wang GH, Lu J, Ma KL, et al. The release of monocyte-derived tissue factor-positive microparticles contributes to a hypercoagulable state in idiopathic membranous nephropathy [J]. J Atheroscler Thromb, 2019, 26(6): 538-546.
[16]	Chen G, Liu H, Liu F. A glimpse of the glomerular milieu: from endothelial cell to thrombotic disease in nephrotic syndrome [J]. Microvasc Res, 2013, 89: 1-6.
[17]	Llach F. Hypercoagulability, renal vein thrombosis, and other thrombotic complications of nephrotic syndrome [J]. Kidney Int, 1985, 28(3): 429-439.
[18]	Beck LH Jr, Salant DJ. Refining our understanding of the PLA2R-antibody response in primary membranous nephropathy: looking forward, looking back [J]. J Am Soc Nephrol, 2020, 31(1): 8-11.
[19]	刘蕾，乐伟波，徐孝东，等. 特发性膜性肾病凝血功能障碍与血小板功能亢进的关联[J]. 肾脏病与透析肾移植杂志，2017, 26(2): 108-112,152.
[20]	Gyamlani G, Molnar MZ, Lu JL, et al. Association of serum albumin level and venous thromboembolic events in a large cohort of patients with nephrotic syndrome [J]. Nephrol Dial Transplant, 2017, 32(1): 157-164.
[21]	金金，王亚红，王红燕，等. 肾静脉栓塞的彩色多普勒超声征象及其诊断价值[J/CD]. 中华医学超声杂志(电子版), 2018, 15(4): 258-262.
[22]	Kim JH, Lim KM, Gwak HS. New anticoagulants for the prevention and treatment of venous thromboembolism [J]. Biomol Ther (Seoul), 2017, 25(5): 461-470.
[23]	Beck L, Bomback AS, Choi MJ, et al. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for glomerulonephritis [J]. Am J Kidney Dis, 2013, 62(3): 403-441.
[24]	Medjeral-Thomas N, Ziaj S, Condon M, et al. Retrospective analysis of a novel regimen for the prevention of venous thromboembolism in nephrotic syndrome [J]. Clin J Am Soc Nephrol, 2014, 9(3): 478-483.
[25]	Eneman B, Levtchenko E, van den Heuvel B, et al. Platelet abnormalities in nephrotic syndrome [J]. Pediatr Nephrol, 2016, 31(8): 1267-1279.
[26]	Lee T, Biddle AK, Lionaki S, et al. Personalized prophylactic anticoagulation decision analysis in patients with membranous nephropathy [J]. Kidney Int, 2014, 85(6): 1412-1420.
[27]	Kelddal S, Nykjær KM, Gregersen JW, et al. Prophylactic anticoagulation in nephrotic syndrome prevents thromboembolic complications [J]. BMC Nephrol, 2019, 20(1): 139.
[28]	Sexton DJ, de Freitas DG, Little MA, et al. Direct-acting oral anticoagulants as prophylaxis against thromboembolism in the nephrotic syndrome [J]. Kidney Int Rep, 2018, 3(4): 784-793.
[29]	Kearon C, Akl EA, Ornelas J, et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report [J]. Chest, 2016, 149(2): 315-352.
[30]	Zhang L, Zhang H, Zhang J, et al. Rivaroxaban for the treatment of venous thromboembolism in patients with nephrotic syndrome and low AT-III: a pilot study [J]. Exp Ther Med, 2018, 15(1): 739-744.
[31]	Reynolds ML, Nachman PH, Mooberry MJ, et al. Recurrent venous thromboembolism in primary membranous nephropathy despite direct Xa inhibitor therapy [J]. J Nephrol, 2019, 32(4): 669-672.
[32]	Lim HY, O′Malley C, Donnan G, et al. A review of global coagulation assays-is there a role in thrombosis risk prediction? [J]. Thromb Res, 2019, 179: 45-55.
[33]	Hincker A, Feit J, Sladen RN, et al. Rotational thromboelastometry predicts thromboembolic complications after major non-cardiac surgery [J]. Crit Care, 2014, 18(5): 549.
[34]	Brill JB, Badiee J, Zander AL, et al. The rate of deep vein thrombosis doubles in trauma patients with hypercoagulable thromboelastography [J]. J Trauma Acute Care Surg, 2017, 83(3): 413-419.

Please choose a citation manager

Content to export